Alterity Therapeutics (ATHE) Institutional Ownership $5.17 +0.16 (+3.11%) As of 10:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Alterity Therapeutics (NASDAQ:ATHE)CurrentInstitutional OwnershipPercentage2.14%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$252.42KNumber ofInstitutional Sellers(last 12 months)0 Get ATHE Insider Trade Alerts Want to know when executives and insiders are buying or selling Alterity Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ATHE Institutional Buying and Selling by Quarter Alterity Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/17/2025 Greenleaf Trust17,000$70K0.0%N/A0.192% 5/7/2025 HB Wealth Management LLC37,483$129K0.0%+17.6%0.423% 2/17/2025Point72 Asset Management L.P.32,627$108K0.0%N/A0.373% 2/17/2025BNP Paribas Financial Markets8,790$29K0.0%N/A0.101% 1/15/2025 HB Wealth Management LLC31,883$110K0.0%+34.1%0.436% 2/4/2022 Envestnet Asset Management Inc.82,386$59K0.0%N/A0.364% 8/13/2021Renaissance Technologies LLC237,903$309K0.0%+5.9%1.052% 5/21/2021Citadel Advisors LLC65,011$94K0.0%N/A0.288% 5/19/2021Virtu Financial LLC69,905$101K0.0%N/A0.309% 5/18/2021Morgan Stanley627,907$904K0.0%+7.9%2.778% 5/18/2021Citadel Advisors LLC65,011$94K0.0%N/A0.288% (Data available from 1/1/2016 forward) ATHE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ATHE shares? During the previous two years, the following institutional investors and hedge funds held shares of Alterity Therapeutics shares: HB Wealth Management LLC ($129K), Point72 Asset Management L.P. ($108K), and Greenleaf Trust ($70K), BNP Paribas Financial Markets ($29K).Learn more on Alterity Therapeutics' institutional investors. What percentage of Alterity Therapeutics' stock is owned by institutional investors? 2.14% of Alterity Therapeutics' stock is owned by institutional investors. Learn more on ATHE's institutional investor holdings. Which institutional investors have been buying Alterity Therapeutics' stock? The following institutional investors have purchased Alterity Therapeutics' stock in the last 24 months: Point72 Asset Management L.P. ($32.63K), Greenleaf Trust ($17K), HB Wealth Management LLC ($13.70K), and BNP Paribas Financial Markets ($8.79K). How much institutional buying is happening at Alterity Therapeutics? Institutional investors have bought a total of 72,117 shares in the last 24 months. This purchase volume represents approximately $252.42K in transactions. Related Companies DSGN Institutional Ownership VTYX Institutional Ownership RAPT Institutional Ownership MDWD Institutional Ownership TLSA Institutional Ownership ELDN Institutional Ownership DMAC Institutional Ownership YMAB Institutional Ownership CRBU Institutional Ownership FDMT Institutional Ownership This page (NASDAQ:ATHE) was last updated on 8/4/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Altcoin That Could be Poised to Benefit Most from Trump’s ReturnWith Trump back in office, the crypto tide is turning fast. Regulation is easing. Momentum is building. And ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
